Clinical Trial Update: Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating MRD assessment combined with a personalized vaccine to prevent postoperative recurrence in epithelial ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer

Snippet

Sponsor: Second Affiliated Hospital of Wenzhou Medical University | Conditions: Epithelial Ovarian Cancer | Phase 2, Phase 3 | Status: RECRUITING